dMed goes global through Clinipace merger ahead of planned Hong Kong listing

dMed’s merger with N.C.-based Clinipace adds new geographies to the CRO’s network ahead of its planned listing on the Hong Kong stock exchange. 

“This gives us the ability to serve biotechs on a global basis with white glove service that is more attuned to the needs of smaller companies,” George Baeder, chief strategy officer of dMed Biopharmaceutical Co. Ltd., told BioCentury. ...